Analysts expect Antares Pharma, Inc. (NASDAQ:ATRS) to post earnings of ($0.03) per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Antares Pharma’s earnings, with the lowest EPS estimate coming in at ($0.04) and the highest estimate coming in at ($0.02). Antares Pharma reported earnings of ($0.04) per share during the same quarter last year, which indicates a positive year over year growth rate of 25%. The firm is expected to issue its next quarterly earnings report on Tuesday, August 8th.

According to Zacks, analysts expect that Antares Pharma will report full year earnings of ($0.13) per share for the current financial year, with EPS estimates ranging from ($0.16) to ($0.11). For the next fiscal year, analysts anticipate that the company will report earnings of $0.00 per share, with EPS estimates ranging from ($0.11) to $0.15. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Antares Pharma.

Antares Pharma (NASDAQ:ATRS) last announced its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.01. Antares Pharma had a negative return on equity of 45.05% and a negative net margin of 41.26%. The company had revenue of $12.01 million during the quarter, compared to analyst estimates of $12.10 million.

ATRS has been the subject of several analyst reports. Raymond James Financial, Inc. initiated coverage on Antares Pharma in a research note on Thursday, April 20th. They issued a “strong-buy” rating and a $4.30 price objective for the company. Vetr downgraded Antares Pharma from a “strong-buy” rating to a “buy” rating and set a $3.47 price objective for the company. in a research note on Monday, June 26th. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of Antares Pharma in a research note on Friday, June 23rd. Finally, Chardan Capital initiated coverage on Antares Pharma in a research note on Friday, June 23rd. They issued a “buy” rating and a $5.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $3.50.

In related news, insider Fred M. Powell acquired 130,000 shares of the stock in a transaction dated Friday, June 9th. The stock was purchased at an average cost of $2.79 per share, with a total value of $362,700.00. Following the completion of the purchase, the insider now directly owns 331,434 shares in the company, valued at approximately $924,700.86. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 11.60% of the company’s stock.

Several hedge funds have recently modified their holdings of ATRS. Rubric Capital Management LP increased its stake in shares of Antares Pharma by 103.7% in the first quarter. Rubric Capital Management LP now owns 2,371,970 shares of the specialty pharmaceutical company’s stock worth $6,736,000 after buying an additional 1,207,622 shares during the last quarter. Morgan Stanley increased its stake in shares of Antares Pharma by 153.3% in the first quarter. Morgan Stanley now owns 996,113 shares of the specialty pharmaceutical company’s stock worth $2,829,000 after buying an additional 602,834 shares during the last quarter. Laurion Capital Management LP acquired a new stake in shares of Antares Pharma during the first quarter worth approximately $1,373,000. Goldman Sachs Group Inc. increased its stake in shares of Antares Pharma by 338.0% in the first quarter. Goldman Sachs Group Inc. now owns 576,664 shares of the specialty pharmaceutical company’s stock worth $1,638,000 after buying an additional 445,009 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Antares Pharma by 10.3% in the first quarter. Renaissance Technologies LLC now owns 3,152,569 shares of the specialty pharmaceutical company’s stock worth $8,953,000 after buying an additional 293,228 shares during the last quarter. 32.04% of the stock is owned by institutional investors.

WARNING: This piece of content was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/07/17/0-03-eps-expected-for-antares-pharma-inc-atrs-this-quarter.html.

Shares of Antares Pharma (ATRS) remained flat at $3.29 during mid-day trading on Monday. 1,154,012 shares of the company’s stock traded hands. Antares Pharma has a 12-month low of $0.98 and a 12-month high of $3.37. The firm has a 50-day moving average price of $2.76 and a 200-day moving average price of $2.58. The firm’s market cap is $513.00 million.

About Antares Pharma

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.

Get a free copy of the Zacks research report on Antares Pharma (ATRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.